Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study

Documenti analoghi

• First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis
  di: Paolo Ghia, et al.
  Pubblicazione: (2024)
• Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
  di: Kostas Stamatopoulos, et al.
  Pubblicazione: (2024)
• A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia
  di: Elisa Lenti, et al.
  Pubblicazione: (2025)
• Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience
  di: Paolo Ghia, et al.
  Pubblicazione: (2025)
• Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
  di: Arnon P. Kater, et al.
  Pubblicazione: (2024)